Medtronic Plc (MDT)

In August 2025, Medtronic reported first-quarter fiscal year 2026 financial results that surpassed analyst expectations. In November 2025, the company announced strong second-quarter fiscal year 2026 financial results and raised its full-year guidance. Between December 2025 and January 2026, analyst ratings and price targets saw adjustments from Truist Financial, Citigroup, and William Blair. In February 2026, a U.S. jury found Medtronic unlawfully monopolized the market for certain vessel-sealing devices, ordering damages to Applied Medical, while Medtronic Diabetes expanded access to its insulin solutions and received new FDA clearances. The retirement of Nina Goodheart was also noted.

Medtronic's products and services generally experience strong demand due to the prevalence of chronic diseases and innovation in digital health, robotics, and AI. The company has reported consistent mid-single-digit organic revenue growth, indicating stable demand. The nature of medical devices for chronic conditions suggests a less pronounced seasonality compared to consumer goods.

Medtronic is a global leader in medical technology, focused on alleviating pain, restoring health, and extending life. Its product portfolio is organized into four segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The Cardiovascular Portfolio includes devices like pacemakers and stent grafts. The Neuroscience Portfolio offers neurostimulation devices and spinal technologies. The Medical Surgical Portfolio encompasses minimally invasive surgical solutions and robotic-assisted surgery platforms. The Diabetes segment provides therapies for individuals with diabetes, including insulin-delivery systems.

Medtronic has a significant global presence, operating in over 150 countries with more than 95,000 employees across 350 locations. Key regional hubs are strategically located across the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

Medtronic's brand reputation has been influenced by both positive and negative events. Positive developments include consistent U.S. FDA approvals across various segments. A negative impact was the February 2026 U.S. jury finding that the company unlawfully monopolized the market for certain vessel-sealing devices, resulting in an order to pay approximately $382 million in damages.

Medtronic is largely controlled by institutional shareholders, who collectively own approximately 87% of the company. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., State Street Corp., J.P. Morgan Chase & Co., and Capital Research Global Investors. Vanguard Group, Inc. is the largest shareholder with 9.8% of shares outstanding.